Loading
A phase 3 trial of Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Mabscale, LLC, now recruiting.
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05654454 by Mabscale, LLC, with 620 participants planned, started 2023-05-31 and due to reach its primary completion in 2026-12. Interventions recorded: Bevacizumab, Paclitaxel, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.